Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cadila Pharmaceuticals Limited
Cadila Pharmaceuticals Limited
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Regulatory
India QC issues could hinder growth in US
Increase in regulatory scrutiny comes after the share of India-made products in the US market increased from 18% to 33% in the five years to 2014
Regulatory
Indian pricing authority to address overcharging by pharma companies
NPPA has decided to chase drug majors for defaulting on penalties that have been imposed for overcharging consumers for medicines
Regulatory
Several large Indian pharma companies under US FDA scrutiny
Recent regulatory action by the FDA on leading Indian firms has affected the country's exports, according to Chairman of Dr. Reddy's Laboratories
Manufacturing
Moberg and Cadila agree development and marketing deal for bupivacaine
Cadila will conduct a Phase III programme in India
Pharmaceutical
India and China set to dominate biosimilars market
Annual growth rate for biosimilars in India and China could reach 30% in 2014-18
Finance
Operating margins expected to grow by 28% year-on-year for Indian pharma firms
Most are focusing on niche products in the US
Research & Development
Helperby Therapeutics and Cadila sign antibiotic drug resistance agreement
Cadila will take a new Helperby compound through Phase III trials, approvals and into commercialisation
Subscribe now